BioDiscovery, Inc. a leader in integrated software solutions for genomics data analysis for life sciences, announced today the release of NxClinical 2.0, a comprehensive software solution for molecular genetics and cytogenomics labs. NxClinical is a flexible, platform-agnostic database solution for efficient analysis, interpretation, and reporting of genomic variations.
NxClinical 2.0 is a multi-user system with a central database easily accessible from anywhere. Using standardized and automated processes, NxClinical increases overall productivity and consistency in the entire workflow. In version 2.0, software improvements include the incorporation of additional databases such as OMIM® (Online Mendelian Inheritance in Man) and ClinVar, ISCN (International System for Human Cytogenetic Nomenclature) notation in reports, and HPO (Human Phenotype Ontology) terms for samples enabling scoring of variants based on genes implicated in specific phenotypes, all contributing to further speeding up of event interpretation.
“With increased use of high throughput technologies and the shear amount of data produced, BioDiscovery realizes the necessity for fast, accurate, and consistent reporting,” said Dr. Soheil Shams, CEO, BioDiscovery Inc. “This can only be achieved by highly automating processes and integrating reference databases to aid the reviewer with aberration interpretation.”
NxClinical’s platform-agnostic hallmark allows labs to use the same software for analysis and interpretation of data from various manufacturers allowing much greater flexibility and ease in changing vendors or technologies without having to invest additional time and money in installation, training, and validation with a new system. The automated workflow can be customized to mirror a lab’s decision making process and classification terms to pre-classify events, removing repetitive tasks and minimizing potential human error. The system allows enforcement of lab SOPs with assigned user roles and privileges for appropriate user access, extensive audit trail capabilities, and flexible deployment with local or cloud-based options.
“The unique VIA (Variant Interpretation Assistant) in NxClinical uses lab-defined rules to pre-classify events,” said Dr. Shams. “In 2.0, an added feature allows the system to learn from previous interpretations of events to further speed up the case review process. The automated workflow greatly reduces time spent on repetitive tasks and decreases the total turnaround time for case review and reporting.”
BioDiscovery will officially launch NxClinical 2.0 during the European Human Genetics Conference (ESHG) 2015, June 6-9 in Glasgow, Scotland. Conference attendees have the opportunity to visit BioDiscovery at booth #240 to analyze and interpret their own microarray data through NxClinical. Learn more about NxClinical and ESHG.
Please note the following:
OMIM® and Online Mendelian Inheritance in Man® are registered trademarks of the Johns Hopkins University.
About BioDiscovery, Inc.
BioDiscovery, Inc. is dedicated to the development of state-of-the-art software products for life science research as well as clinical applications. The company’s mission is to enable scientists to eliminate disease and suffering through application of computational technologies and translating these findings directly and rapidly to clinical use. From its inception in 1997, BioDiscovery has been an innovative leader in the genomics field having introduced the first dedicated commercial software tool for analyzing microarray images. Since then, innovation has continued to be a top priority. BioDiscovery’s passion to make a difference has further extended the company’s reach into creating the most comprehensive enterprise-wide system enabling research findings to translate into clinical applications and make direct impact on patient care. For more information, visit http://www.biodiscovery.com.